Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.36 |
| ▸ | MGLL | Q99685 | 3/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TACR3 | P29371 | 5/20 | 0.34 |
| ▸ | TACR2 | P21452 | 3/20 | 0.34 |
| ▸ | TACR1 | P25103 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6423941 | 0.98 | PTGS2 (0.43) | PTGS2PTGS1AKR1C3AKR1C2MGLL | |
| SCHEMBL6426823 | 0.92 | PTGS2 (0.42) | PTGS2PTGS1AKR1C3AKR1C2MGLL | |
| SCHEMBL6425904 | 0.92 | PTGS2 (0.45) | PTGS2PTGS1GAA | |
| SCHEMBL6427348 | 0.90 | PTGS2 (0.42) | PTGS2PTGS1AKR1C3AKR1C2MGLL | |
| SCHEMBL6423232 | 0.90 | PTGS2 (0.45) | PTGS2PTGS1GAA | |
| SCHEMBL6423781 | 0.89 | PDE2A (0.35) | PTGS2AKR1C3AKR1C2MGLLPDE2A | |
| SCHEMBL5560154 | 0.88 | PTGS2 (0.56) | PTGS2PTGS1AKR1C3AKR1C2 | |
| SCHEMBL6425963 | 0.87 | PDE2A (0.35) | PTGS2AKR1C3AKR1C2MGLLPDE2A | |
| SCHEMBL6423884 | 0.86 | PTGS2 (0.56) | PTGS2PTGS1AKR1C3AKR1C2 | |
| SCHEMBL5554564 | 0.85 | PTGS2 (0.49) | PTGS2PTGS1AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGES2 | PTGS2 4/4885PTGS1 7/4885AKR1C3 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.